LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 222

Search options

  1. Article ; Online: Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print].

    Correa, Rohann J M / Louie, Alexander V / Zaorsky, Nicholas G / Lehrer, Eric J / Ellis, Rodney / Ponsky, Lee / Kaplan, Irving / Mahadevan, Anand / Chu, William / Swaminath, Anand / Hannan, Raquibul / Onishi, Hiroshi / Teh, Bin S / Muacevic, Alexander / Lo, Simon S / Staehler, Michael / Siva, Shankar

    European urology focus

    2019  Volume 7, Issue 2, Page(s) 404–405

    MeSH term(s) Carcinoma, Renal Cell ; Humans ; Kidney Neoplasms ; Male ; Prostatic Neoplasms/surgery ; Radiosurgery
    Language English
    Publishing date 2019-11-01
    Publishing country Netherlands
    Document type Letter ; Comment
    ISSN 2405-4569
    ISSN (online) 2405-4569
    DOI 10.1016/j.euf.2019.10.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Evaluating an Academic Radiation Oncology Position.

    Zaorsky, Nicholas G / Trifiletti, Daniel M / Vapiwala, Neha

    Practical radiation oncology

    2024  

    Abstract: What are the factors that physicians could consider in an academic radiation oncology practice job offer? In this minireview, we discuss how prospective academic faculty could evaluate the "big 3" domains: (1) the compensation, including the direct and ... ...

    Abstract What are the factors that physicians could consider in an academic radiation oncology practice job offer? In this minireview, we discuss how prospective academic faculty could evaluate the "big 3" domains: (1) the compensation, including the direct and indirect payments; (2) the daily job, including aspects of the clinic, research, and education; and (3) the location, including geography, atmosphere, environment, and culture. If a prospective academic radiation oncologist believes that the academic practice is "great" in at least 2 of the 3 and "good" in the remaining 1, then they should likely sign the contract.
    Language English
    Publishing date 2024-02-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2655748-4
    ISSN 1879-8519 ; 1879-8500
    ISSN (online) 1879-8519
    ISSN 1879-8500
    DOI 10.1016/j.prro.2024.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Prostate and Pelvis on Pause Pending a Pandemic.

    Zaorsky, Nicholas G

    International journal of radiation oncology, biology, physics

    2020  Volume 108, Issue 2, Page(s) 341–342

    MeSH term(s) Coronavirus ; Humans ; Male ; Pandemics ; Pelvis ; Prostatic Neoplasms/epidemiology
    Keywords covid19
    Language English
    Publishing date 2020-09-03
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2020.07.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Radiation Therapy for Renal Cell Carcinoma.

    Zaorsky, Nicholas G / Louie, Alexander V / Siva, Shankar

    International journal of radiation oncology, biology, physics

    2023  Volume 117, Issue 3, Page(s) 523–525

    MeSH term(s) Humans ; Carcinoma, Renal Cell/radiotherapy ; Kidney Neoplasms/radiotherapy
    Language English
    Publishing date 2023-06-19
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2023.03.073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Radiation therapy options in kidney cancer.

    Zaorsky, Nicholas G / Louie, Alexander V / Siva, Shankar

    Current opinion in supportive and palliative care

    2023  Volume 17, Issue 4, Page(s) 308–314

    Abstract: Purpose of review: In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).: Recent findings: For primary RCC treated with SBRT, local control is ...

    Abstract Purpose of review: In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).
    Recent findings: For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.
    Summary: Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/radiotherapy ; Carcinoma, Renal Cell/pathology ; Kidney Neoplasms/pathology ; Radiosurgery/adverse effects
    Language English
    Publishing date 2023-10-26
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2633726-5
    ISSN 1751-4266 ; 1751-4258
    ISSN (online) 1751-4266
    ISSN 1751-4258
    DOI 10.1097/SPC.0000000000000683
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?

    Zaorsky, Nicholas G / Spratt, Daniel E

    International journal of radiation oncology, biology, physics

    2021  Volume 111, Issue 4, Page(s) 965–967

    MeSH term(s) Humans ; Male ; Prostatic Neoplasms/radiotherapy ; Radiotherapy, Conformal
    Language English
    Publishing date 2021-10-13
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2021.07.1699
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Causes of death among people living with metastatic cancer.

    Mani, Kyle / Deng, Daxuan / Lin, Christine / Wang, Ming / Hsu, Melinda L / Zaorsky, Nicholas G

    Nature communications

    2024  Volume 15, Issue 1, Page(s) 1519

    Abstract: ... versus other causes (e.g., stroke, heart disease, etc.). Among 1,030,937 US (1992-2019) metastatic cancer ...

    Abstract Studying survivorship and causes of death in patients with advanced or metastatic cancer remains an important task. We characterize the causes of death among patients with metastatic cancer, across 13 cancer types and 25 non-cancer causes and predict the risk of death after diagnosis from the diagnosed cancer versus other causes (e.g., stroke, heart disease, etc.). Among 1,030,937 US (1992-2019) metastatic cancer survivors, 82.6% of patients (n = 688,529) died due to the diagnosed cancer, while 17.4% (n = 145,006) died of competing causes. Patients with lung, pancreas, esophagus, and stomach tumors are the most likely to die of their metastatic cancer, while those with prostate and breast cancer have the lowest likelihood. The median survival time among patients living with metastases is 10 months; our Fine and Gray competing risk model predicts 1 year survival with area under the receiver operating characteristic curve of 0.754 (95% CI [0.754, 0.754]). Leading non-cancer deaths are heart disease (32.4%), chronic obstructive and pulmonary disease (7.9%), cerebrovascular disease (6.1%), and infection (4.1%).
    MeSH term(s) Male ; Humans ; Cause of Death ; Breast Neoplasms ; Risk Factors ; Causality ; Heart Diseases
    Language English
    Publishing date 2024-02-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-024-45307-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A population-based study of COVID-19 mortality risk in US cancer patients.

    Mani, Kyle A / Wu, Xue / Spratt, Daniel E / Wang, Ming / Zaorsky, Nicholas G

    Journal of the National Cancer Institute

    2024  

    Abstract: Background: In this study, we provide the largest analysis to date of a US-based cancer cohort to characterize death from COVID-19.: Methods: A total of 4,020,669 patients across 15 subtypes living with cancer in 2020 and included in the National ... ...

    Abstract Background: In this study, we provide the largest analysis to date of a US-based cancer cohort to characterize death from COVID-19.
    Methods: A total of 4,020,669 patients across 15 subtypes living with cancer in 2020 and included in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were abstracted. We investigated prognostic factors for death due to COVID-19 using a cox proportional hazards model and calculated hazard ratios (HRs). Standardized mortality ratios (SMRs) were calculated using observed mortality counts from SEER and expected mortality based on U.S. mortality rates.
    Results: 291,323 patients died, with 14,821 (5.1%) deaths attributed to COVID-19 infection. The COVID-19 disease-specific mortality rate was 11.81/10,000-persons years, and SMR of COVID-19 was 2.30 (95% CI: 2.26-2.34, p < .0001). COVID-19 ranked as the second leading cause of death following ischemic heart disease (5.2%) among 26 non-cancer causes of death. Patients who are older (80+ vs < =49 years old: HR 21.47, 95% CI: 19.34-23.83), male (vs female: HR 1.46, 95% CI: 1.40-1.51), unmarried (vs married: HR 1.47, 95% CI: 1.42-1.53), and Hispanic or Non-Hispanic African American (vs Non-Hispanic White: HR 2.04, 95% CI: 1.94-2.14 and HR 2.03, 95% CI: 1.94-2.14, respectively) were at greatest risk of COVID-19 mortality.
    Conclusions and relevance: We observed that people living with cancer are at two times greater risk of dying from COVID-19 compared to the general US population. This work may be used by physicians and public health officials in the creation of survivorship programs that mitigate the risk of COVID-19 mortality.
    Language English
    Publishing date 2024-04-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djae086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Salvage therapy at biochemical recurrence of prostate cancer.

    Zaorsky, Nicholas G / Kishan, Amar U

    Nature reviews. Urology

    2020  Volume 17, Issue 4, Page(s) 195–196

    MeSH term(s) Humans ; Male ; Prostate-Specific Antigen ; Prostatectomy ; Prostatic Neoplasms/surgery ; Salvage Therapy
    Chemical Substances Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2020-08-24
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/s41585-020-0290-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top